TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors

cMet is a well‐characterized oncogene that is the target of many drugs including small molecule and biologic pathway inhibitors, and, more recently, antibody–drug conjugates (ADCs). However, the clinical benefit from cMet‐targeted therapy has been limited. We developed a novel cMet‐targeted ‘third‐g...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Mol Oncol
Κύριοι συγγραφείς: Gymnopoulos, Marco, Betancourt, Oscar, Blot, Vincent, Fujita, Ryo, Galvan, Diana, Lieuw, Vincent, Nguyen, Sophie, Snedden, Jeanette, Stewart, Christine, Villicana, Jose, Wojciak, Jon, Wong, Eley, Pardo, Raul, Patel, Neki, D’Hooge, Francois, Vijayakrishnan, Balakumar, Barry, Conor, Hartley, John A., Howard, Philip W., Newman, Roland, Coronella, Julia
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley and Sons Inc. 2019
Θέματα:
Research Articles
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6944112/
https://ncbi.nlm.nih.gov/pubmed/31736230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12600
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια